Pricing Log in Create free account

Palvella Therapeutics, Inc. (PVLA) vs Arcus Biosciences, Inc. (RCUS)

Palvella Therapeutics, Inc. and Arcus Biosciences, Inc. are both Biotechnology companies. Arcus Biosciences, Inc. is the larger, with a market value of $2.5B against $2.3B — 1.1× the size. Palvella Therapeutics, Inc. grew revenue faster over the last twelve months: 146.7% against −58.3%. Palvella Therapeutics, Inc. has the higher net margin (0.00% vs −453.0%) and the higher return on invested capital (0.00% vs 0.00%). Across the 16 metrics below, Palvella Therapeutics, Inc. leads on 12 and Arcus Biosciences, Inc. on 4.

Valuation

Metric PVLA RCUS Biotechnology median
P/E n/m n/m 10.60
P/S 60.13 23.30 9.40
P/B 11.52 6.51 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m n/m 0.66
EV/Sales 54.13 18.02 9.02
Earnings yield (2.77%) (19.87%) (32.88%)
Free cash flow yield (1.28%) (20.04%) (23.13%)

Profitability

Metric PVLA RCUS Biotechnology median
Gross margin 100.00% 100.00% 68.51%
Operating margin 0.00% (475.00%) 0.00%
Net margin 0.00% (453.00%) 0.00%
Free cash flow margin 0.00% (465.00%) 0.00%
Return on equity (46.63%) (114.11%) (51.96%)
Return on assets (37.70%) (50.56%) (46.06%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric PVLA RCUS Biotechnology median
Revenue growth (TTM) 146.67% (58.33%) 6.76%
EPS growth (last fiscal year) 52.62% (4.78%) 29.88%
Revenue growth, 5-year CAGR 8.03% 25.93% 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric PVLA RCUS Biotechnology median
Debt to equity 0.00 0.28 0.00
Current ratio 21.18 3.34 4.97
Net debt to EBITDA 1.50 2.27 1.01

Dividend

Metric PVLA RCUS Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric PVLA RCUS Biotechnology median
Market cap 2.26b 2.51b 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack